ZECUITY Drug Patent Profile
✉ Email this page to a colleague
When do Zecuity patents expire, and what generic alternatives are available?
Zecuity is a drug marketed by Teva Branded Pharm and is included in one NDA. There are nine patents protecting this drug.
This drug has ninety-two patent family members in fourteen countries.
The generic ingredient in ZECUITY is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zecuity
A generic version of ZECUITY was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.
Summary for ZECUITY
International Patents: | 92 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 70 |
Clinical Trials: | 1 |
Patent Applications: | 5,500 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ZECUITY at DailyMed |
Recent Clinical Trials for ZECUITY
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
NuPathe Inc. | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for ZECUITY
US Patents and Regulatory Information for ZECUITY
ZECUITY is protected by nine US patents.
Patents protecting ZECUITY
Transdermal methods and systems for the delivery of anti-migraine compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
Pharmacokinetics of iontophoretic sumatriptan administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
Polyamine enhanced formulations for triptan compound iontophoresis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
Transdermal methods and systems for the delivery of anti-migraine compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
Pharmacokinetics of iontophoretic sumatriptan administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Electronic control of drug delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
Transdermal methods and systems for the delivery of anti-migraine compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
User-activated self-contained co-packaged iontophoretic drug delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
Pharmacokinetics of iontophoretic sumatriptan administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZECUITY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZECUITY
See the table below for patents covering ZECUITY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hong Kong | 1205026 | 給藥系統的電子控制 (ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM) | ⤷ Sign Up |
European Patent Office | 2012871 | MÉTHODES ET SYSTÈMES TRANSDERMIQUES D'ADMINISTRATION DE COMPOSÉS ANTI-MIGRAINE (TRANSDERMAL METHODS AND SYSTEMS FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS) | ⤷ Sign Up |
Japan | 2014221798 | 抗片頭痛化合物の送達のための経皮的方法およびシステム (TRANSDERMAL METHODS AND SYSTEMS FOR DELIVERY OF ANTI-MIGRAINE COMPOUNDS) | ⤷ Sign Up |
New Zealand | 610790 | Transdermal methods and systems for the delivery of anti-migraine compounds | ⤷ Sign Up |
European Patent Office | 2810688 | Commande électronique pour système d'administration de médicament (Electronic control of drug delivery system) | ⤷ Sign Up |
Japan | 2006513768 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |